Microinvasive squamous cell carcinoma of the cervix: Immunohistochemically detected prognostic factors in a case with poor clinical outcome

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 443-445

  Kohlberger, Petra ^a   Edwards, Lyndall ^b   Hacker, Neville F ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Immunohistochemistry; Microinvasive cervical cancer; Prognosis

Indexed keywords

BIOLOGICAL MARKER; HERMES ANTIGEN; INTERSTITIAL COLLAGENASE; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN;

ABDOMINAL CANCER; ADULT; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; DISEASE MARKER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LYMPH NODE; LYMPHADENECTOMY; ONCOGENE NEU; PAIN; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; UTERINE CERVIX CARCINOMA;

EID: 0043125615     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00250-6     Document Type: Article

References (10)

1. Annual Report on the results of Treatment in Gynaecological Cancer. J Epiderm Biostat. 6:2001;5-44.
2. Elliott P., Coppleson M., Russell P., Liouros P., Carter J., MacLeod C., Jones M. Early invasive (FIGO stage IA) carcinoma of the cervix a clinico-pathologic study of 476 cases . Int J Gynecol Cancer. 10:2000;42-52.
3. Ostor A.G., Rome R.M. Micro-invasve squamous cell carcinoma of the cervix a clinico-pathologic study of 200 cases with long term follow up . Int J Gynecol Cancer. 4:1994;257-264.
4. Morris M. Management of stage la cervical carcinoma. J Natl Cancer Inst Monogr. 21:1996;47-52.
5. Speiser P., Kridelka F., Tempfer C., Edwards L., Leodolter S., Kainz C., Hacker N.F. CD44v6 expression is an independent prognostic factor in node-negative FIGO stage IB cervical carcinoma. Int J Gynecol Cancer. 9:1999;160-165.
6. Nevin J., Laing D., Kaye P., McCulloch T., Bamard R., Silcocks P., Blackett T., Paterson M., Sharp F., Cruse P. The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol. 73:1999;254-258.
7. Chen H.Y., Hsu C.T., Lin W.C., Tsai H.D., Chang W.C. Prognostic value of p53 expression in stage IB1 cervical carcinoma. Gynecol Obstet Invest. 49:2000;266-271.
8. Dimitrakakis C., Kymionis G., Diakomanolis E., Papaspyrou I., Rodolakis A., Arzimanoglou I., Leandros E., Michalas S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol. 77:2000;129-136.
9. Moser P.L., Kieback D.G., Hefler L., Tempfer C., Neunteufel W., Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP2) in stage IB cervical cancer. Anticancer Res. 19:1999;4391-4393.
10. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer. 80:1999;827-833.